O3R-5671

O3R-5671 is a highly selective, oral small molecule inhibitor of salt-inducible kinase 3 (SIK3), designed specifically to avoid the toxicities associated with inhibition of related kinases SIK1 and SIK2. It does not inhibit other kinases, demonstrating specificity and a favorable safety profile in preclinical testing. O3R-5671 targets immune dysregulation in autoimmune diseases by potently inhibiting the release of inflammatory cytokines (TNFα, IL-12, IL-23) and promoting the release of the anti-inflammatory cytokine IL-10. Preclinical efficacy has been shown in animal models of inflammatory bowel disease and psoriasis, matching current standards of care. The drug is being developed by Onco3R Therapeutics for oral administration and is in Phase 1 clinical trials for multiple autoimmune diseases, including ulcerative colitis, Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis. Its improved selectivity and toxicity profile aim to overcome limitations of earlier SIK inhibitors and provide a well-tolerated, effective, and convenient therapeutic option[1][2][3][4][5][6][7][8][9][11][13][14].

Brand names

O3R-5671O-3R-5671O 3R-5671

Other names

O3R-5671O-3R-5671O 3R-5671